Multifunctional theranostic nanocarrier platform for microglia-selective cytochalasin D delivery to modulate neuroinflammation after acute brain injuries
Source abstract
Abstract
Targeting microglia to modulate neuroinflammation after acute brain injuries (ABIs) is promising but limited by poor blood-brain barrier (BBB) penetration and systemic toxicity of candidate agents. In addition, multifunctional platforms combining targeted therapy with real-time traceability remain limited. We developed and characterized a multifunctional theranostic, folate-functionalized, polydopamine (PDA)-coated mesoporous silica nanoparticle (FA-NP) system for microglia-selective delivery and intracellular release of cytoskeleton inhibitor Cytochalasin D (CytoD). FA-NPs exhibited ideal physicochemical properties for parenchymal brain accumulation and pH-sensitive PDA shells enabled intracellular retention and gradual degradation. Using radiolabeled and fluorescein-isothiocyanate-functionalized FA-NPs, SPECT/CT imaging, γ-counting, autoradiography, and immunohistochemistry confirmed parenchymal brain accumulation with cellular uptake following systemic administration. Activated microglia upregulated folate receptors (FOLR1/2) and internalized FA-NPs via FOLR-mediated, dynamin-dependent endocytosis. CytoD-loaded FA-NPs (FA-NP[CytoD]) significantly reduced microglial migration, phagocytosis, ROS production, and proinflammatory cytokines, outperforming molecular CytoD while exhibiting notably lower toxicity compared to both CytoD and unfunctionalized particles. In organotypic brain slice models of hypoxia-reoxygenation and traumatic injury, FA-NP[CytoD] reduced inflammation at 24 and 96 h. Systemic administration enabled brain accumulation with clearance over time. Together, this multifunctional theranostic platform integrates selective microglial targeting, controlled drug release, and multimodal imaging, offering translational potential for ABIs.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Global, regional, and national burden of disorders affecting the nervous system, 1990–2021: a systematic analysis for the Global Burden of Disease Study 202110.1016/S1474-4422(24)00038-3 ↗
2. The global burden of neurological disorders: translating evidence into policy10.1016/S1474-4422(19)30411-9 ↗
3. Global, regional, and national burden of ischemic stroke, 1990–2021: an analysis of data from the global burden of disease study 202110.1016/j.eclinm.2024.102758 ↗
4. The blood-brain barrier: Physiology and strategies for drug delivery10.1016/j.addr.2019.11.009 ↗
5. From blood–brain barrier to blood–brain interface: new opportunities for CNS drug delivery10.1038/nrd.2015.21 ↗
6. The blood–brain barrier: Structure, regulation and drug delivery10.1038/s41392-023-01481-w ↗
7. Multi-disciplinary Approach for Drug and Gene Delivery Systems to the Brain10.1208/s12249-021-02144-1 ↗
8. Global Epidemiology of Stroke and Access to Acute Ischemic Stroke Interventions10.1212/WNL.0000000000012781 ↗
9. The Epidemiology of Fatal Occupational Traumatic Brain Injury in the U.S10.1016/j.amepre.2011.03.007 ↗
10. Microglia in Neurological Diseases: A Road Map to Brain-Disease Dependent-Inflammatory Response10.3389/fncel.2018.00488 ↗
11. The semantics of microglia activation: neuroinflammation, homeostasis, and stress10.1186/s12974-021-02309-6 ↗
12. Physiology of Microglia10.1152/physrev.00011.2010 ↗
13. Microglia in the TBI brain: The good, the bad, and the dysregulated10.1016/j.expneurol.2015.08.018 ↗
14. Microglia states and nomenclature: A field at its crossroads10.1016/j.neuron.2022.10.020 ↗
15. The microglial sensome revealed by direct RNA sequencing10.1038/nn.3554 ↗
16. Microglia Responses to Pro-inflammatory Stimuli (LPS, IFNγ+TNFα) and Reprogramming by Resolving Cytokines (IL-4, IL-10)10.3389/fncel.2018.00215 ↗
17. Neuroinflammation and M2 microglia: the good, the bad, and the inflamed10.1186/1742-2094-11-98 ↗
18. Microglial M1/M2 polarization and metabolic states10.1111/bph.13139 ↗
19. Microglia/Macrophage Polarization Dynamics Reveal Novel Mechanism of Injury Expansion After Focal Cerebral Ischemia10.1161/STROKEAHA.112.659656 ↗
20. Identification of Two Distinct Macrophage Subsets with Divergent Effects Causing either Neurotoxicity or Regeneration in the Injured Mouse Spinal Cord10.1523/JNEUROSCI.3257-09.2009 ↗
21. Current Knowledge of Microglia in Traumatic Spinal Cord Injury10.3389/fneur.2021.796704 ↗
22. Role of Microglia in Neurotrauma10.1016/j.nurt.2010.07.002 ↗
23. How to reprogram microglia toward beneficial functions10.1002/glia.23484 ↗
24. Cytochalasin D inhibits actin polymerization and induces depolymerization of actin filaments formed during platelet shape change10.1038/293302a0 ↗
25. Primary phagocytosis of viable neurons by microglia activated with LPS or Aβ is dependent on calreticulin/LRP phagocytic signalling10.1186/1742-2094-9-196 ↗
26. Accelerated Phagocytosis of Amyloid-β by Mouse and Human Microglia Overexpressing the Macrophage Colony-stimulating Factor Receptor10.1074/jbc.M200868200 ↗
27. Tolerated doses in zebrafish of cytochalasins and jasplakinolide for comparison with tolerated doses in mice in the evaluation of pre-clinical activity of microfilament-directed agents in tumor model systems in vivo
28. Tunable synthesis, characterization, and CMP performance of dendritic mesoporous silica nanospheres as functionalized abrasives10.1016/j.colsurfa.2022.128322 ↗
29. High Surface Area Mesoporous Silica Nanoparticles with Tunable Size in the Sub-Micrometer Regime: Insights on the Size and Porosity Control Mechanisms10.3390/molecules26144247 ↗
30. Biocompatibility, physico-chemical and mechanical properties of hydroxyapatite-based silicon dioxide nanocomposites for biomedical applications10.1016/j.ceramint.2020.06.132 ↗
31. Current trends in silica based drug delivery systems
32. The Toxicity of Silica Nanoparticles to the Immune System10.2217/nnm-2018-0076 ↗
33. Size-dependent immune-modulating effect of amorphous nanosilica particles
34. Silica Nanoparticles Decrease Glutamate Uptake in Blood–Brain Barrier Components10.1007/s12640-024-00696-1 ↗
35. Silica-Based Nanoparticle Uptake and Cellular Response by Primary Microglia10.1289/ehp.0901534 ↗
36. Four types of inorganic nanoparticles stimulate the inflammatory reaction in brain microglia and damage neurons in vitro10.1016/j.toxlet.2012.08.009 ↗
37. Silica Nanoparticles Cause Activation of NLRP3 Inflammasome in-vitro Model-Using Microglia10.2147/IJN.S372485 ↗
38. Subacute silica nanoparticle exposure induced oxidative stress and inflammation in rat hippocampus combined with disruption of cholinergic system and behavioral functions10.1016/j.impact.2021.100358 ↗
39. Brain Accumulation and Toxicity Profiles of Silica Nanoparticles: The Influence of Size and Exposure Route10.1021/acs.est.1c07562 ↗
40. Polydopamine Nanomaterials for Overcoming Current Challenges in Cancer Treatment10.3390/nano13101656 ↗
41. Polydopamine-coated mesoporous silica nanoparticles for multi-responsive drug delivery and combined chemo-photothermal therapy10.1016/j.msec.2019.110103 ↗
42. Mussel-inspired polydopamine coated mesoporous silica nanoparticles as pH-sensitive nanocarriers for controlled release10.1016/j.ijpharm.2013.12.045 ↗
43. pH-Responsive Magnetic Mesoporous Silica-Based Nanoplatform for Synergistic Photodynamic Therapy/Chemotherapy10.1021/acsami.7b19797 ↗
44. Polydopamine-Coated Manganese Carbonate Nanoparticles for Amplified Magnetic Resonance Imaging-Guided Photothermal Therapy10.1021/acsami.7b03087 ↗
45. A versatile ethanol-mediated polymerization of dopamine for efficient surface modification and the construction of functional core–shell nanostructures10.1039/c3tb21028f ↗
46. Asn-Gly-Arg-modified polydopamine-coated nanoparticles for dual-targeting therapy of brain glioma in rats10.18632/oncotarget.12047 ↗
47. Melanin-like polydopamine nanoparticles mediating anti-inflammatory and rescuing synaptic loss for inflammatory depression therapy10.1186/s12951-023-01807-4 ↗
48. Folate receptor-targeted positron emission tomography of experimental autoimmune encephalomyelitis in rats10.1186/s12974-019-1612-3 ↗
49. Molecular Targets for PET Imaging of Activated Microglia: The Current Situation and Future Expectations10.3390/ijms18040802 ↗
50. The Atypical Antipsychotic Paliperidone Regulates Endogenous Antioxidant/Anti-Inflammatory Pathways in Rat Models of Acute and Chronic Restraint Stress10.1007/s13311-016-0438-2 ↗
51. Validation of Dual-Action Chemo-Radio-Labeled Nanocarriers with High Efficacy against Triple-Negative Breast Cancer10.1021/acsami.3c10579 ↗
52. Folate receptor-targeted nanoparticle delivery of HuR-RNAi suppresses lung cancer cell proliferation and migration10.1186/s12951-016-0201-1 ↗
53. A Novel Folate-Targeted Nanoliposomal System of Doxorubicin for Cancer Targeting10.1208/s12249-015-0462-2 ↗
54. Inhibitor analysis revealed that clathrin-mediated endocytosis is involed in cellular entry of type III grass carp reovirus10.1186/s12985-018-0993-8 ↗
55. Recent advances on the use of biodegradable microparticles and nanoparticles in controlled drug delivery10.1016/0378-5173(94)00324-X ↗
56. Silica-based mesoporous nanoparticles for controlled drug delivery10.1177/2041731413503357 ↗
57. Mesoporous silica nanoparticles in target drug delivery system: A review10.4103/2230-973X.160844 ↗
58. Mesoporous silica nanoparticles as delivery carriers: An overview of drug loading techniques
59. Mesoporous Silica Nanoparticles for Reducing Hemolytic Activity Towards Mammalian Red Blood Cells10.1002/smll.200800926 ↗
60. Mesoporous silica nanoparticles for therapeutic/diagnostic applications10.1016/j.biopha.2018.10.167 ↗
61. Size‐Dependent Cytotoxicity of Monodisperse Silica Nanoparticles in Human Endothelial Cells10.1002/smll.200800461 ↗
62. The effect of size, morphology and surface properties of mesoporous silica nanoparticles on pharmacokinetic aspects and potential toxicity concerns10.3389/fmats.2023.1189463 ↗
63. Key for crossing the BBB with nanoparticles: the rational design10.3762/bjnano.11.72 ↗
64. Effect of light and temperature on zeta potential and physical stability in solid lipid nanoparticle (SLNTM) dispersions10.1016/S0378-5173(98)00092-1 ↗
65. Drug Delivery to the Brain across the Blood–Brain Barrier Using Nanomaterials10.1002/smll.201701921 ↗
66. Nanoparticle Surface Charges Alter Blood–Brain Barrier Integrity and Permeability10.1080/10611860400015936 ↗
67. LDLR-mediated peptide-22-conjugated nanoparticles for dual-targeting therapy of brain glioma10.1016/j.biomaterials.2013.08.039 ↗
68. Bridging Size and Charge Effects of Mesoporous Silica Nanoparticles for Crossing the Blood–Brain Barrier
69. Towards multifunctional, targeted drug delivery systems using mesoporous silica nanoparticles – opportunities & challenges10.1039/c0nr00156b ↗
70. Single and repeated dose toxicity of mesoporous hollow silica nanoparticles in intravenously exposed mice10.1016/j.biomaterials.2010.10.035 ↗
71. Size-dependent internalization of particles via the pathways of clathrin- and caveolae-mediated endocytosis10.1042/bj20031253 ↗
72. Caveolin-1, caveolae, and glioblastoma10.1093/neuonc/nos079 ↗
73. FolR1: a novel cell surface marker for isolating midbrain dopamine neural progenitors and nascent dopamine neurons10.1038/srep32488 ↗
74. Novel localization of folate transport systems in the murine central nervous system10.1186/s12987-022-00391-3 ↗
75. Folate receptor 1 is necessary for neural plate cell apical constriction during Xenopus neural tube formation10.1242/dev.137315 ↗
76. Noncanonical function of folate through folate receptor 1 during neural tube formation10.1038/s41467-024-45775-1 ↗
77. Early Fate Defines Microglia and Non-parenchymal Brain Macrophage Development10.1016/j.cell.2020.03.021 ↗
78. Transcriptomic diversity of cell types across the adult human brain10.1126/science.add7046 ↗
79. Spatiotemporal transcriptomic atlas of mouse organogenesis using DNA nanoball-patterned arrays10.1016/j.cell.2022.04.003 ↗
80. Spatiotemporal omics for biology and medicine10.1016/j.cell.2024.07.040 ↗
81. Uncovering the interplay between pH receptors and immune cells: Potential drug targets10.3892/or.2021.8179 ↗
82. Biocompatible mesoporous silica nanoparticles with different morphologies for animal cell membrane penetration10.1016/j.cej.2007.09.045 ↗
83. Size Effect on Cell Uptake in Well‐Suspended, Uniform Mesoporous Silica Nanoparticles10.1002/smll.200900005 ↗
84. Pathways of clathrin-independent endocytosis10.1038/nrm2216 ↗
85. Designing Mesoporous Silica Nanoparticles to Overcome Biological Barriers by Incorporating Targeting and Endosomal Escape10.1021/acsami.0c21507 ↗
86. The Endosomal Escape of Nanoparticles: Toward More Efficient Cellular Delivery10.1021/acs.bioconjchem.8b00732 ↗
87. Intracerebral fate of organic and inorganic nanoparticles is dependent on microglial extracellular vesicle function10.1038/s41565-023-01551-8 ↗
88. Cytotoxicity of mesoporous silica nanomaterials10.1016/j.jinorgbio.2007.12.028 ↗
89. A pH-responsive mesoporous silica nanoparticles-based multi-drug delivery system for overcoming multi-drug resistance10.1016/j.biomaterials.2011.06.066 ↗
90. Biodistribution and toxicity of intravenously administered silica nanoparticles in mice10.1007/s00204-009-0488-x ↗
91. Safe Nanoparticles: Are We There Yet?10.3390/ijms22010385 ↗
92. Polyglycerol/Polydopamine-Coated Nanoparticles for Biomedical Applications10.3389/fmats.2022.878455 ↗
93. Recent Advances in a Polydopamine-Mediated Antimicrobial Adhesion System10.3389/fmicb.2020.607099 ↗
94. Chemotherapy in vivo against M109 murine lung carcinoma with cytochalasin B by localized, systemic, and liposomal administration10.1007/s10637-014-0202-6 ↗
95. Polydopamine-based surface modification of mesoporous silica nanoparticles as pH-sensitive drug delivery vehicles for cancer therapy10.1016/j.jcis.2015.11.001 ↗
96. Mediating the Fate of Cancer Cell Uptake: Dual-Targeted Magnetic Nanovectors with Biotin and Folate Surface Ligands10.1021/acsbiomaterials.0c00771 ↗
97. Erythropoietin Enhances Post-ischemic Migration and Phagocytosis and Alleviates the Activation of Inflammasomes in Human Microglial Cells10.3389/fncel.2022.915348 ↗
98. Microglial-specific depletion of TAK1 is neuroprotective in the acute phase after ischemic stroke10.1007/s00109-020-01916-9 ↗
99. Regulation of Hypoxia-Induced Inflammatory Responses and M1-M2 Phenotype Switch of Primary Rat Microglia by Sex Steroids10.1007/s12031-013-0137-y ↗
100. Sex steroid hormone-mediated functional regulation of microglia-like BV-2 cells during hypoxia10.1016/j.jsbmb.2013.06.003 ↗